Skip to content

Study · Animal study (in vivo) · dog and mouse · 2020

5 results

Subacute Toxicity Study of Nicotinamide Mononucleotide via Oral Administration.

You Y, Gao Y, Wang H, Li J, Zhang X, Zhu Z, Liu N

Frontiers in pharmacology15 Dec 2020Cited by 9 (Europe PMC)

PMID33384603 (opens in a new tab)PMCIDPMC7770224 (opens in a new tab)DOI10.3389/fphar.2020.604404 (opens in a new tab)PepBankPUB-33384603
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

Nicotinamide mononucleotide (NMN), a key precursory metabolite of NAD+, has been shown to elevate the cellular level of NAD+ and ameliorate various age-related diseases. Despite these progresses, systemic evaluation pertaining to the subacute toxicity of NMN remains to be determined. Here, we examine the subacute toxicity of NMN in mice and beagle dogs. Mice were gavaged with a saturated concentration of NMN solution at the maximum intragastric dose once or twice per day for 7 days. Dogs were gavaged twice per day for 14 days. In mice, NMN administrated once per day for 7 days is well tolerated with minimal deleterious effects. Upon higher dosage, we observe slightly increased level of alamine aminotransferase, while other biomarkers remain unchanged. Consistently, administration of NMN in beagle dogs only results in mild increases in creatinine and uric acid. Together, our study highlights the safety of NMN, providing a possible safe dose range for oral administration of NMN.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In mice, once-daily oral NMN for 7 days was well tolerated with minimal deleterious effects.

    In plain wordsIn mice, oral NMN once daily for 7 days caused minimal harmful effects.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Not applicableTolerability
    Study

    mousen: not reported in source

    Subacute toxicity study
    Outcome group
    Adverse events · Whole body
    Studied dose
    Maximum intragastric dose once daily · oral gavage · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    In mice, NMN administrated once per day for 7 days is well tolerated with minimal deleterious effects.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In mice, higher-dose NMN slightly increased alamine aminotransferase levels.

    In plain wordsIn mice, higher-dose NMN slightly increased the reported liver enzyme level.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseAlamine aminotransferase
    Study

    mousen: not reported in source

    Subacute toxicity study
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · oral gavage · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    Upon higher dosage, we observe slightly increased level of alamine aminotransferase, while other biomarkers remain unchanged.
    1 context sentence
    Summary · context
    Mice were gavaged with a saturated concentration of NMN solution at the maximum intragastric dose once or twice per day for 7 days.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In mice, other biomarkers remained unchanged with higher-dose NMN.

    In plain wordsIn mice, higher-dose NMN did not change other reported biomarkers.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeOther biomarkers
    Study

    mousen: not reported in source

    Subacute toxicity study
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · oral gavage · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    Upon higher dosage, we observe slightly increased level of alamine aminotransferase, while other biomarkers remain unchanged.
    1 context sentence
    Summary · context
    Mice were gavaged with a saturated concentration of NMN solution at the maximum intragastric dose once or twice per day for 7 days.
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In beagle dogs, NMN mildly increased creatinine.

    In plain wordsIn beagle dogs, NMN mildly increased creatinine levels.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseCreatinine
    Study

    dogn: not reported in source

    Beagle dogs
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · oral gavage · 14 daysAs given in this study (dog).

    Source sentences

    Summary
    Consistently, administration of NMN in beagle dogs only results in mild increases in creatinine and uric acid.
    1 context sentence
    Summary · context
    Dogs were gavaged twice per day for 14 days.
  5. 05AnimalAnimal study (in vivo)Safety outcome

    In beagle dogs, NMN mildly increased uric acid.

    In plain wordsIn beagle dogs, NMN mildly increased uric acid levels.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseUric acid
    Study

    dogn: not reported in source

    Beagle dogs
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · oral gavage · 14 daysAs given in this study (dog).

    Source sentences

    Summary
    Consistently, administration of NMN in beagle dogs only results in mild increases in creatinine and uric acid.
    1 context sentence
    Summary · context
    Dogs were gavaged twice per day for 14 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.